The Role of Routine Diagnostic Radioiodine Whole-Body Scintigraphy in Patients with High-Risk Differentiated Thyroid Cancer

被引：19
|
作者：
de Meer, Siegrid G. [1 ]
Vriens, Menno R. [1 ]
Zelissen, Pierre M. [2 ]
Rinkes, Inne H. Borel [1 ]
de Keizer, Bart [3 ]
机构：
[1] Univ Med Ctr Utrecht, Dept Surg, Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Endocrinol, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Nucl Med, Utrecht, Netherlands
来源：
JOURNAL OF NUCLEAR MEDICINE | 2011年 / 52卷 / 01期
关键词：
endocrinology; oncology; diagnostic value; diagnostic whole-body scintigraphy; well-differentiated thyroid cancer; SERUM THYROGLOBULIN; FOLLOW-UP; CARCINOMA; PAPILLARY; SCAN; METASTASIS; MANAGEMENT; CONSENSUS; ABLATION; THERAPY;
D O I：
10.2967/jnumed.110.080697
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Follow-up diagnostic radioiodine whole-body scintigraphy (DxWBS) is still advised for high-risk patients with differentiated thyroid cancer. The aim of this study was to evaluate the additional value of DxWBS to stimulated thyroglobulin measurement in high-risk patients. Methods: The results of DxWBS and thyroglobulin measurements performed 6-12 mo after surgery and radioiodine thyroid remnant ablation in patients with differentiated thyroid cancer were retrospectively evaluated for 112 patients with high-risk features for recurrence (R3/T4 and N1). Results: One patient had an undetectable thyroglobulin level, with DxWBS results suggestive of cervical recurrence. DxWBS was found to be false-positive. Of the patients with detectable thyroglobulin levels, the DxWBS results were negative in 65 and positive in only 8. The 6 patients positive for thyroglobulin antibody had negative DxWBS results. The remaining patients had an undetectable thyroglobulin level and negative DxWBS results. Conclusion: Because undetectable stimulated thyroglobulin levels have a negative predictive value of 100%, DxWBS offers no information additional to recombinant human thyroid-stimulating hormone-stimulated thyroglobulin measurements in patients with high-risk differentiated thyroid cancer.
引用
收藏
页码：56 / 59
页数：4
相关论文
共 50 条
  • [31] Impact of aditional radioiodine treatment in well differentiated thyroid carcinoma in patients with negative whole-body scan and high thyroglobulin level
    Rocha, C.
    Vieira, F.
    Costa, G.
    Albuquerque, A.
    Freitas, D.
    Silva, F.
    Ferrer-Antunes, A.
    de Lima, J. Pedroso
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S330 - S330
  • [32] Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2*)
    Dietlein, M
    Dressler, J
    Eschner, W
    Leisner, B
    Reiners, C
    Schicha, H
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2003, 42 (03): : 123 - 125
  • [33] Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3)
    Dietlein, M.
    Dressler, J.
    Eschner, W.
    Gruenwold, F.
    Lassmann, M.
    Leisner, B.
    Luster, M.
    Reiners, C.
    Schicha, H.
    Schober, O.
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2007, 46 (05): : 206 - 212
  • [34] Evaluation of Parotid Salivary Gland Echo Texture by Ultrasound Examinations and Correlation With Whole-Body Scintigraphy After Radioiodine Therapy in Patients With Differentiated Thyroid Carcinoma
    Lima, Graziele Aparecida Simoes
    Lopez, Rossana Veronica Mendoza
    de Freitas, Ricardo Miguel Costa
    Willegaignon, Jose
    Sapienza, Marcelo Tatit
    Chammas, Maria Christina
    Coura-Filho, George Barberio
    [J]. JOURNAL OF ULTRASOUND IN MEDICINE, 2020, 39 (09) : 1811 - 1818
  • [35] Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH
    Bacher, Robin
    Hohberg, Melanie
    Dietlein, Markus
    Wild, Markus
    Kobe, Carsten
    Drzezga, Alexander
    Schmidt, Matthias
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (05) : 631 - 637
  • [36] Disseminated bone marrow metastases of insular thyroid carcinoma detected by radioiodine whole-body scintigraphy
    Rufini, V
    Salvatori, M
    Saletnich, I
    Luzi, S
    Fadda, G
    Shapiro, B
    Troncone, L
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (04) : 633 - 636
  • [37] Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
    Pitoia, Fabian
    Marlowe, Robert J.
    Abelleira, Erika
    Faure, Eduardo N.
    Bueno, Fernanda
    Schwarzstein, Diego
    Julio Lutfi, Ruben
    Niepomniszcze, Hugo
    [J]. JOURNAL OF THYROID RESEARCH, 2012, 2012
  • [38] Predictive value of FDG PET at initial radioiodine therapy for survival of high-risk patients with differentiated thyroid cancer
    Gaertner, Florian
    Okamoto, Shozo
    Shiga, Tohru
    Ito, Yoichi
    Uchiyama, Yuko
    Manabe, Osamu
    Hattori, Naoya
    Tamaki, Nagara
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [39] Diagnostic Value of Recombinant Human Thyrotropin-Stimulated 123I Whole-Body Scintigraphy in the Follow-Up of Patients With Differentiated Thyroid Cancer
    Alzahrani, Ali S.
    AlShaikh, OmAlkhaire
    Tuli, Mahmoud
    Al-Sugair, Abdulaziz
    Alamawi, Reem
    Al-Rasheed, Maha M.
    [J]. CLINICAL NUCLEAR MEDICINE, 2012, 37 (03) : 229 - 234
  • [40] Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer
    Fang, Andrew M.
    Chapin, Brian F.
    Shi, Charles W.
    Sun, Jia
    Qayyum, Aliya
    Kundra, Vikas
    Corn, Paul G.
    Kuban, Deborah A.
    Ravizzini, Gregory C.
    Surasi, Devaki Shilpa S.
    Ma, Jingfei
    Bathala, Tharakeswara K.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2024,
12345